8-K 1 form8k091101.txt -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2001 (September 6, 2001) BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction (Commission (IRS Employer Identification of incorporation) File Number) No.) 371 Bel Marin Keys Boulevard, 94949 Suite 210 (Zip Code) Novato, California (Address of principal executive offices) (415) 884-6700 (Registrant's telephone number, including area code) -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- Item 5. Other Events Effective September 6, 2001, Ansbert Gadicke, MD, has resigned from the Board of Directors of BioMarin. Dr. Gadicke is the Managing Director of MPM Capital LLC and served as a member of the BioMarin Board of Directors since December 1997. MPM Capital is the beneficial holder of 3,212,560 shares or 7.6 % of BioMarin's common stock. The Board elected Phyllis Gardner, MD, Senior Associate Dean for Education and Student Affairs, Stanford University School of Medicine, to take Dr. Gadicke's position on the Board. Item 7. Financial Statements and Exhibits None SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioMarin Pharmaceutical Inc. By: /s/ Raymond W. Anderson ------------------------------------------------- Raymond W. Anderson Chief Operating Officer, Chief Financial Officer, Secretary and Vice President Finance and Administration Date: September 11, 2001